Recent News

• 03.31.2025 - ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
• 03.31.2025 - ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
• 03.27.2025 - ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
• 03.27.2025 - ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
• 03.07.2025 - ProPhase Labs to Present at the Investor Summit Virtual on March 11
• 03.07.2025 - ProPhase Labs to Present at the Investor Summit Virtual on March 11
• 02.25.2025 - ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
• 02.25.2025 - ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
• 02.25.2025 - ProPhase Labs presentation as of 2.25.2025
• 02.20.2025 - ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables

Recent Filings

• 03.31.2025 - 8-K Current report
• 03.31.2025 - EX-99.1 EX-99.1
• 03.28.2025 - S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
• 03.25.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.21.2025 - 3 Initial statement of beneficial ownership of securities
• 02.21.2025 - 8-K Current report
• 02.21.2025 - 4 Statement of changes in beneficial ownership of securities